CN101218238B - 咪唑并[1,2-a]吡啶衍生物：制备及药学应用 - Google Patents

咪唑并[1,2-a]吡啶衍生物：制备及药学应用 Download PDF

Info

Publication number
CN101218238B
CN101218238B CN2006800092539A CN200680009253A CN101218238B CN 101218238 B CN101218238 B CN 101218238B CN 2006800092539 A CN2006800092539 A CN 2006800092539A CN 200680009253 A CN200680009253 A CN 200680009253A CN 101218238 B CN101218238 B CN 101218238B
Authority
CN
China
Prior art keywords
cancer
compound
group
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800092539A
Other languages
English (en)
Chinese (zh)
Other versions
CN101218238A (zh
Inventor
李志立
艾瑞克T·孙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
SBio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBio Pte Ltd filed Critical SBio Pte Ltd
Publication of CN101218238A publication Critical patent/CN101218238A/zh
Application granted granted Critical
Publication of CN101218238B publication Critical patent/CN101218238B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
CN2006800092539A 2005-03-21 2006-03-20 咪唑并[1,2-a]吡啶衍生物：制备及药学应用 Expired - Fee Related CN101218238B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66326505P 2005-03-21 2005-03-21
US60/663,265 2005-03-21
US75954406P 2006-01-18 2006-01-18
US60/759,544 2006-01-18
PCT/SG2006/000064 WO2006101455A1 (en) 2005-03-21 2006-03-20 Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications

Publications (2)

Publication Number Publication Date
CN101218238A CN101218238A (zh) 2008-07-09
CN101218238B true CN101218238B (zh) 2011-10-26

Family

ID=37024054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800092539A Expired - Fee Related CN101218238B (zh) 2005-03-21 2006-03-20 咪唑并[1,2-a]吡啶衍生物：制备及药学应用

Country Status (12)

Country Link
EP (1) EP1863811B1 (enExample)
JP (1) JP5206405B2 (enExample)
KR (1) KR101300831B1 (enExample)
CN (1) CN101218238B (enExample)
AR (1) AR056187A1 (enExample)
AU (1) AU2006225355B2 (enExample)
CA (1) CA2602328C (enExample)
ES (1) ES2470766T3 (enExample)
MX (1) MX2007011710A (enExample)
MY (1) MY147647A (enExample)
TW (1) TW200714600A (enExample)
WO (1) WO2006101455A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
WO2008029152A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP2064211B1 (en) * 2006-09-20 2015-11-11 MEI Pharma, Inc. Imidazo[1,2-a]pyridine hydroxymate compounds that are inhibitors of histone deacetylase
KR20090094336A (ko) 2006-11-27 2009-09-04 하. 룬트벡 아크티에 셀스카브 헤테로아릴 아미드 유도체
WO2008068392A1 (fr) * 2006-12-07 2008-06-12 Commissariat A L'energie Atomique Nouveaux derives fluorophores imidazo [1,2-a] pyridin-3-yl-amine et leur procede de preparation
EP2155744A1 (en) 2007-04-10 2010-02-24 Lundbeck, H., A/S Heteroaryl amide analogues as p2x7 antagonists
WO2008134553A1 (en) * 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
US20110206607A1 (en) * 2007-05-10 2011-08-25 Roger Olsson Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
US8481572B2 (en) 2007-08-09 2013-07-09 Urifer Ltd. Pharmaceutical compositions and methods for the treatment of cancer
DE102007040336A1 (de) 2007-08-27 2009-03-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
JP2011502133A (ja) * 2007-11-02 2011-01-20 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
EP2300470A2 (en) 2008-05-19 2011-03-30 Sepracor Inc. Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators
WO2010032195A1 (en) * 2008-09-16 2010-03-25 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
US20110212943A1 (en) * 2008-10-15 2011-09-01 Orchid Research Laboratories Limited Novel bridged cyclic compounds as histone deacetylase inhibitors
WO2012018932A2 (en) * 2010-08-03 2012-02-09 The Regents Of The University Of California Compounds and compositions for mitigating tissue damage and lethality
EP2671582B1 (en) 2011-02-01 2016-07-13 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
CA2831356A1 (en) * 2011-03-31 2012-10-04 Emblem Technology Transfer Gmbh Imidazo [1,2-a]pyridine_compounds for use in therapy
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2881394B1 (en) * 2012-07-31 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Condensed ring heterocyclic compound
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CA2909477A1 (en) * 2013-04-30 2014-11-06 F. Hoffmann-La Roche Ag Pd-catalyzed coupling of pyrazole amides
JP2016527184A (ja) * 2013-05-24 2016-09-08 イオメット ファーマ リミテッド Ｓｌｃ２ａ輸送体阻害剤
KR102314290B1 (ko) * 2013-06-25 2021-10-21 에프. 호프만-라 로슈 아게 척수성 근위축증을 치료하기 위한 화합물
EP3062783B1 (en) 2013-10-18 2020-08-12 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
WO2017030938A1 (en) * 2015-08-14 2017-02-23 Incyte Corporation Heterocyclic compounds and uses thereof
WO2018048261A1 (ko) * 2016-09-08 2018-03-15 가천대학교 산학협력단 신규 스피로퀴논 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 신경계 질환의 예방 또는 치료용 약학적 조성물
EP4019607B1 (en) 2020-12-22 2024-05-15 Essilor International Electrochromic compounds and optical articles containing them
CN113321651B (zh) * 2021-06-22 2022-06-14 四川省医学科学院·四川省人民医院 吡唑并吡啶异羟肟酸类化合物、其制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1292697A (zh) * 1998-05-20 2001-04-25 伊莱利利公司 抗病毒化合物
CN1306533A (zh) * 1998-04-29 2001-08-01 阿斯特拉曾尼卡有限公司 抑制胃酸分泌的咪唑并吡啶衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221996A (en) 1986-10-07 1989-08-29 Yamanouchi Pharma Co Ltd Imidazo-pyridine derivatives and pharmaceutical compositions
JPH11505524A (ja) * 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US7169801B2 (en) * 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
TW200501897A (en) 2003-07-10 2005-01-16 Kung-Sheng Pan Shoes electrostatically embedded with objects
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
WO2005085214A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd ジアリール置換複素５員環誘導体
KR20070009614A (ko) * 2004-03-17 2007-01-18 알타나 파마 아게 7ｈ-8,9-디히드로-피라노(2,3-ｃ)이미다조(1,2-ａ)피리딘유도체 및 이의 위산 분비 억제제로서의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306533A (zh) * 1998-04-29 2001-08-01 阿斯特拉曾尼卡有限公司 抑制胃酸分泌的咪唑并吡啶衍生物
CN1292697A (zh) * 1998-05-20 2001-04-25 伊莱利利公司 抗病毒化合物

Also Published As

Publication number Publication date
KR101300831B1 (ko) 2013-08-30
JP2008533198A (ja) 2008-08-21
ES2470766T3 (es) 2014-06-24
EP1863811B1 (en) 2014-03-12
EP1863811A4 (en) 2008-11-12
AU2006225355B2 (en) 2010-12-09
CN101218238A (zh) 2008-07-09
JP5206405B2 (ja) 2013-06-12
KR20080005207A (ko) 2008-01-10
CA2602328C (en) 2014-07-29
MX2007011710A (es) 2007-11-20
TW200714600A (en) 2007-04-16
AU2006225355A1 (en) 2006-09-28
WO2006101455A1 (en) 2006-09-28
MY147647A (en) 2012-12-31
EP1863811A1 (en) 2007-12-12
AR056187A1 (es) 2007-09-26
CA2602328A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
CN101218238B (zh) 咪唑并[1,2-a]吡啶衍生物：制备及药学应用
US8648092B2 (en) Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
US8703794B2 (en) Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
WO1999037622A1 (en) Nitrogenous heterocyclic derivatives and medicine thereof
WO2006101456A1 (en) Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
EP2600719A1 (en) 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
CN101448506A (zh) 通过抑制有丝分裂酶激酶治疗癌症的吡咯并三嗪衍生物
US9115149B2 (en) Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections
CN101815715B (zh) 7-炔基-1,8-萘啶酮的衍生物、其制备和其在治疗学中的应用
WO2018121774A1 (zh) 一种选择性抑制激酶化合物及其用途
WO1997023482A1 (en) 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives
CN100546980C (zh) 苯并咪唑衍生物:制备方法及医药应用
TW201300390A (zh) 喹□啉化合物
WO2015085860A1 (zh) 杂环羟肟酸类化合物及其药用组合物和应用
WO2006101454A1 (en) Benzothiophene derivatives: preparation and pharmaceutical applications
TWI557122B (zh) 咪唑并吡啶衍生物之醫療用途
CN101287712B (zh) 杂环化合物
EP2064211B1 (en) Imidazo[1,2-a]pyridine hydroxymate compounds that are inhibitors of histone deacetylase
Blackburn i, United States Patent (10) Patent No.: US 8,901,149 B2
AU2006220413A1 (en) Compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: MEIER PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: S*

Effective date: 20131023

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20131023

Address after: American California

Patentee after: Mel pharmaceuticals, Limited by Share Ltd

Address before: Singapore Singapore

Patentee before: S. Bio Pte Ltd.

TR01 Transfer of patent right

Effective date of registration: 20200227

Address after: Lugano, Switzerland

Patentee after: HELSINN HEALTHCARE S.A.

Address before: California, USA

Patentee before: Mel pharmaceuticals, Limited by Share Ltd

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111026

Termination date: 20210320

CF01 Termination of patent right due to non-payment of annual fee